On October 5, 2023 Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, reported that long-term data regarding Cesium-131 brachytherapy in the treatment of prostate cancer, as well as preliminary long-term data of Cesium-131 utilized in salvage treatment of recurrent cervical and uterine cancers were presented at the American Society for Radiation Oncology’s (ASTRO) Annual Conference held in San Diego, from October 1-4, 2023 (Press release, Perspective Therapeutics, OCT 5, 2023, View Source [SID1234635687]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first presentation, entitled "Long-Term Urinary Toxicity Follow-Up of Combined External Beam Radiation and Cs-131 LDR Brachytherapy Boost for Prostate Cancer," was presented by Mohamed Abdelhakiem, MD from the UPMC Hillman Cancer Center in Pittsburgh, PA. The presentation described urinary data collected from 341 patients treated with Cesium-131 between 2006 and 2022.

The second presentation, entitled "Cesium-131 Low-Dose Rate Interstitial Brachytherapy as a Salvage Re-Irradiation Technique in Treating Cervical and Uterine Cancer Pelvic Recurrence with Prior History of Pelvic Radiation," was presented by Zeta Chow, MD, MS from the University of Kentucky in Lexington, KY. The aim of the study was to report local cancer control rates and the toxicity profile of Cesium 131 brachytherapy as a salvage re-irradiation option for patients with recurrent disease. The authors concluded that Cesium-131 brachytherapy is a promising alternative to pelvic exenteration, which can be a significant surgical procedure.

"We’re excited that UPMC’s long term data on Cesium-131 brachytherapy for prostate cancer was included at this year’s ASTRO meeting," said Thijs Spoor, Perspective’s Chief Executive Officer. "ASTRO’s inclusion of the University of Kentucky’s promising data describing Cesium-131 brachytherapy in a challenging group of gynecological patients reinforces its value as the isotope of choice for brachytherapy treatment in multiple tumors."

Perspective Therapeutics is the world’s only producer of Cesium-131 seeds for brachytherapy which provide expanding internal radiation treatment options throughout the body for prostate cancer as well as difficult to treat lung, brain, gynecological, head and neck, pelvic, and colorectal cancers.

Additional details about these presentations can be found on the ASTRO website (www.astro.org).